The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Android Launch Of Tandem Mobi App

• In March 2026, Tandem Diabetes Care announced that its FDA-cleared Tandem Mobi mobile app is now available to U.S. Android users via Google Play, enabling direct control of the Tandem Mobi automated insulin delivery system from select Google Pixel 6–10 and Samsung Galaxy S21–S25 smartphones.
• This expansion to Android significantly broadens the pool of potential users who can integrate Tandem Mobi into their existing devices, strengthening the appeal of Tandem’s connected diabetes management ecosystem.
• We’ll now examine how extending Tandem Mobi control to compatible Android smartphones could influence Tandem Diabetes Care’s long-term investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Tandem Diabetes Care Investment Narrative Recap

To own Tandem, you need to believe its insulin pump platforms and software can turn growing usage into a path toward profitability, despite recent losses and intensifying competition. The Android rollout for Tandem Mobi may support new pump starts and renewals in the near term, but it does not remove key risks around execution of the multichannel commercial strategy and the pressure that flat 2026 renewals could place on recurring revenue growth.

The most relevant recent announcement alongside the Android launch is Tandem’s February 2026 guidance for full year 2026 sales of about US$1.065 billion to US$1.085 billion. That outlook, set before the broader Mobi Android availability, sits against a backdrop of 2025 sales of roughly US$1.015 billion and a full year net loss of about US$204.7 million, so investors will be watching closely to see whether expanded smartphone compatibility supports management’s revenue targets without worsening losses.

Yet while Mobi’s Android expansion could help address renewal softness, investors should also be aware of the risk that...

Read the full narrative on Tandem Diabetes Care (it's free!)

Tandem Diabetes Care's narrative projects $1.2 billion revenue and $14.4 million earnings by 2028. This requires 7.5% yearly revenue growth and about a $220 million earnings increase from -$205.5 million today.

Uncover how Tandem Diabetes Care's forecasts yield a $28.91 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about 6.1 percent annual revenue growth to roughly US$1.2 billion and no profitability by 2028, painting a far more pessimistic picture than narratives that lean on Mobi momentum or pharmacy expansion, so it is worth comparing these sharply different views as you assess how this new Android launch might reshape expectations.

Explore 4 other fair value estimates on Tandem Diabetes Care - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com